Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database.

Yuichi IshikawaKei TokutsuShingo NakayamadaAya KuchibaKiyohide FushimiShinya MatsudaYoshiya Tanaka

Published in: Annals of the rheumatic diseases (2023)

In life-threatening AAV, RTX has similar short-term effectiveness on mortality to IVCY. Although RTX might have a lower risk of fungal infections and pneumocystis pneumonia, the short-term renal prognosis might be inferior to IVCY.

Keyphrases

randomized controlled trial
systematic review
low dose
cardiovascular events
high dose
diffuse large b cell lymphoma
cardiovascular disease
cross sectional
risk factors
intensive care unit
coronary artery disease
mechanical ventilation
respiratory failure